Ligand just bought its way bigger

Royalty kings, meet consolidation

Ligand Pharmaceuticals is buying XOMA Royalty for about $39 a share, valuing the deal at roughly $739 million. If you’re thinking, “Wait, there are royalty aggregators in biotech?” — yes, and apparently they’re now in the part of the business cycle where the royalty people start buying the royalty people.

Why investors are paying attention

This isn’t just two small-cap names shaking hands for a photo op. It’s a classic scale-and-simplify move:

• Ligand gets a bigger royalty portfolio and more cash-flowing assets under one roof.
• XOMA holders get a takeover premium baked into the deal price.
• The market is basically saying, “Fine, consolidation in biotech can be a thing too.”

Both stocks were higher in pre-market trading, which is Wall Street’s way of saying the math at least makes sense at first glance.

The bigger picture

For Ligand, this could sharpen its identity as a royalty-focused platform instead of a grab bag of biotech exposure. For XOMA, it’s the kind of exit that turns a niche name into a headline and a ticker into a payout story.

Big picture: in a market that loves scale, recurring cash flow, and fewer moving parts, this deal checks a lot of boxes.